Janssen Submits Marketing Authorisation Application to EMA Seeking Approval of Niraparib and Abiraterone Acetate Dual Action Tablet Plus Prednisone for the Treatment of Patients with HRR Gene-Mutated Metastatic Castration Resistant Prostate Cancer
Neuro Central,
The submission to the European Medicines Agency is based on results from the Phase 3 MAGNITUDE study evaluating niraparib in…